Daniel A. Heller, Ph.D. Department of Chemical Engineering, MIT Koch Institute for Integrative Cancer Research, MIT Memorial Sloan-Kettering Cancer Center
Thursday afternoon session: Clinical Connections from Bench to Bedside, Beckman Auditorium, 1:15 PM -- 2:00 PM
Abstract: Metastasis, the spread of cancer cells from a primary tumor to seed secondary tumors in distant sites, is one of the greatest challenges in cancer treatment today. For many patients, by the time cancer is detected, metastasis has already occurred. Over 80% of patients diagnosed with lung cancer, for example, present with metastatic disease. Although cancer therapies are improving, many drugs are not reaching the sites of metastases. Methods that are effective for treating large, well-vascularized tumors may be inadequate when dealing with small clusters of disseminated malignant cells. As the biological mechanisms of metastasis are being unraveled, it is becoming clear that new approaches to treat this condition may become available. The expanding capabilities of the materials sciences, especially in targeting, detection and particle trafficking, will enable novel approaches to treat cancers even after metastatic dissemination. Although the first generation of nano/materials-based drugs has reached the clinic, future systems promise significant advances in targeting metastatic sites and earlier detection through more sensitive imaging techniques.
Speaker bio: Daniel Heller is a Damon Runyon Fellow in Robert S. Langer's laboratory at the David H. Koch Institute for Integrative Cancer Research at MIT. He obtained his BA in History from Rice University in 2000 and a PhD in Chemistry from the University of Illinois in 2010. His work is focused on nanoscale tools for detecting and treating human diseases. He will enter a faculty position at the Memorial Sloan-Kettering Cancer Center and Cornell Medical School in New York City in 2012.
So, welcome back to the Cancer Community at Illinois Symposium.
This afternoon's session will be titled Clinical Connections from Bench to Bedside.
Our first speaker is Dr. Dan Heller, and I'm pleased to welcome him back
because he received his Ph.D. in Chemistry from the University of Illinois in 2010.
Currently, he's a Damon Brennan Fellow in Robert S. Langer's Laboratory
at the David H. Koch Institute for Integrated Cancer Research at MIT.
His work is focused on nanoscale tools for detecting and treating human diseases,
and he will enter a faculty position at the Memorial Sloan-Kettering Cancer Center
and Cornell Medical School in New York City in June.
So, let's welcome our speaker.
Thank you very much, and thank you, Sarah, and thanks to all the organizers,
Eric, and Jay, and the other members of the committee for the Cancer at Illinois,
Cancer Community at Illinois, yes, and for having me back.
It's been, I try to get here as much as possible because I have a lot of good friends here,
and it's a great place to do work, to be a grad student, so you're all lucky.
I did my Ph.D. here, as Sarah said, in Chemistry.
I got my degree in Physical Chemistry, but my advisor is Mike Strano,
and he moved our group four and a half years after I started my Ph.D. to MIT,
though I remained loyal and got my Ph.D. here,
also because he wasn't in the right department and couldn't coach me to the Chemistry department.
But I'm very happy that I got my degree here,
and it started an interesting path from working in Physical Chemistry and then Chemical Engineering,
then to more bio-related stuff, and as Sarah said, I'll be moving to a cancer center,
which really threw me to a loop when I realized that they wanted me.
You'll never know where your path is going to take you.
So in my current position, I'm a fellow in Dr. Edward Langer's laboratory,
also with Dan Anderson, and so I've been doing some of the sRNA therapeutics and a lot of other things.
And one of the things we did when I first got there was,
and then I also realized I had to do cancer stuff,
is that I decided to write a review paper on cancer because I had no idea about anything about it.
So I went into literature and had a colleague that realized that there's really not much in the way of nanomaterials,
which I knew something about, directed toward metastasis.
And we ended up doing a lot of research and found that there's really,
we wrote a 226 citation review where basically saying that there really wasn't much out there,
and on really directing nanomaterials to metastasis.
And it's not really the fault of anyone, it's just, you know, the field is moving.
And so here's a question to wake everybody up.
Someone said something similar to this, or gave you the answer this morning,
so there might be some new people.
How many nanomedicines have been approved by the FDA and are clinically in use,
or allowed to be in use?
And I'll get for hands here.
Are they 0 to 10?
Are there 10 to 50?
Are there, thanks for the audio.
Are there 50 to 100?
Are there over 100?
Okay.
Well, people were, most people were right.
Some people were getting close.
There are actually, so Yang Fang mentioned that there were 24.
If you increase the number to imaging agents, I believe, we get to about 40.
And here they are.
There are, there's a whole list of them in the review out there, not the one I wrote.
And a lot of them are super-powered magnetic iron oxide nanoparticles
that are coated with something.
And they're used for imaging liver and lymph nodes
and they're contrast agents, mostly for MRI.
There's a lot of liposomal drugs, which is good,
because that's pretty much the first nanoparticle drug.
And so doxils on here, along with a lot of other things that came after it.
What else has been approved?
We've got some polymer therapeutics, which some people would say aren't really nano,
but because I titled my talk Material Science for Metastasis,
I would say that conjugating a drug to a polymer falls in that,
at least if you don't believe it's nano.
But so there's all these polymer protein conjugates,
mostly PEG, polyethylene glycol, which is the stealth,
or one of the stealth polymers.
And there's also this, in a class of its own, abraxane,
which is conjugated proteins to deliver a nanoparticle made of proteins
to deliver papotaxel.
And a little bit of radiotherapy conjugates,
which are also just kind of putting two things together.
They're not really nano-sized, you would think.
So there's stuff out there.
And I'm here to really talk to the students and the postdocs.
And if anybody's welcome to pipe up about getting your stuff on this train
to making something useful.
Not only useful for papers, that's good, too,
but also for getting stuff out there.
Because I've been in the Langer Lab.
There's this secret sauce.
Everybody's kind of all entrepreneurial there.
They want to see their stuff at least go to a company.
And so, even though I don't have anything out there,
I've been kind of taking from different people
and learning a lot about, you know, what does it take to go this direction.
And so, but for metastasis, here's another question for you
to wake you up after lunch.
What is the percentage of cancer deaths that are actually due to metastasis
versus the primary tumor?
Are they in the 40 to 60 range?
Are they in the 60 to 80 range?
Are they in the 80 to 90% range?
Are they 100% of all metastasis?
Okay, so I think most people got it.
There are a few that didn't.
At least what I've been reading.
It's something close to 9 out of 10 cancer deaths are due to metastasis.
And the problem is that we're not quite,
at least the nanomaterial people aren't quite there focusing on this.
And I don't know how much we really have to focus directly on metastasis
all the time.
It's also good to think about just cancer as one thing.
Whether it's a primary tumor or a metastasis,
there's mutations and they caused it.
And there's not always different markers or biomarkers that are out there.
But we should be thinking more about, you know, the metastasis
because that's really why people are dying.
And so you can't really get around it.
There's some news out there.
There's some study that found that only 5% of cancer research funds
actually were spent on metastasis when 90% of cancer patients die that way.
That might be slightly misleading because, you know,
we're all thinking about cancer.
But it is interesting to see that really people aren't always focusing
in this direction on that metastasis.
So what can we do as I assume we, meaning a lot of people here are engineers.
I know some people here are biologists.
And I know some people here are bioengineers
and really think they're absolutely both.
I certainly am not both.
One of the big deals is early detection.
If we can just prevent metastasis in the first place
or even if it is metastasized, can we get it?
Can we detect earlier maybe instead of stage 4, stage 3?
But it would be best to detect around stage 1
because that's where it's much more treatable.
So if we can use our nanotechnologies and materials
to go towards early detection, that's a big deal.
Let's make sensors.
I think someone here made these things.
And also let's figure out how to target treatments.
And I found out hanging out with biologists
that when they say targeted therapies,
they don't mean get it into the liver because that's where the cancer is.
They mean get it to focus on a particular pathway and a mechanism.
And that's called targeted from the biologist's point of view.
So there's targeted from the biology.
What is the mechanism?
And then there's targeted from getting it to where the cancer is,
targeting spatially.
And we have to think about both probably.
And we've been, but I think this is one of the main directions.
Can we get the stuff to where we want to go?
And so in terms of the diagnostic side and making sensors,
there's stuff where I think nanomaterials are doing really well.
We can make probes, quantum dots that are super bright,
except the problem is that they're cytotoxic in most cases.
And can we start making things to detect stuff exocellularly but in vivo?
And I'm not even talking about here about in vitro diagnostics,
but we definitely need a lot more of that.
And then can we start making sensors inside of single cells?
And that's kind of where I'm going in the future at Sloan Kettering.
Can we start figuring out what's going on in that single cell?
Because some analytes we can detect, we can detect certain proteins,
but a lot of small molecules we need like a mass spec
and we have to destroy ourselves to actually even detect it.
But there's lots of cool mechanisms out there.
And I don't know, I guess today I didn't hear much about hyperthermia,
but can we heat up cancer cells using nanoparticles that heat up
when we shoot light at them or introduce a rotating magnetic field?
Dan Anderson talked about cell backpacks.
Also recruiting immune cells.
This is what most of us think about with nanotherapies.
Can we release drugs?
But there's so many possibilities out there.
And part of my mission is to get the biologists excited about these things
and to just get them to think, you know,
maybe we can start thinking about all these different options
because I know people think about drugs,
but there's lots of different other possibilities.
And then inducing autophagy and then, of course, gene therapy,
which Dr. K talks about.
And then also just trying to capture the cell,
hook onto the cell and removing it from maybe circulation.
So there's a lot of mechanisms out there
that people have been playing with with nanomaterials.
But this is one of the main problems.
A lot of nanomaterials researchers use this mechanism of targeting.
They take a nanoparticle and then they do really the first thing.
On the biology side, let's make a xenograft.
Let's inject tumor cells into the thigh of a mouse.
And we let it grow until it's really big.
And then let's introduce our nanoparticle.
And you get something like this.
You get a nice lighted up thigh.
And that's cool and that really shows us something
and that can usually make a good paper.
But the problem is that when you do this,
it's really far away from the biology of most tumors,
especially when you're thinking about metastasis.
This is maybe an okay model for a primary tumor,
but for the metastasis it's really not where it is.
If you want to induce, and this is by the way called
the EPR effect, Enhanced Permeation Retention,
you get this big tumor in this area,
and maybe it would be the primary tumor.
But if you're inducing in a mouse, there's one there.
And what happens in a big tumor is that the vasculature
gets really leaky and you can get lots of things
that leak out of those blood vessels into the tissue around it
and then that stuff stays there.
So you can make these nice light up.
But if you have small tumors, maybe metastasis, maybe not,
you don't have that leaky vasculature if it's too small.
And then you're not able to target that way.
So when you are looking towards developing therapies
that are going to metastasis, this is one of the big problems.
You can't really use the easiest way to get something
in the tumor, which is the EPR effect,
which is just due to leaky vasculature,
not allowing things to get in and not allowing it to leave.
But if you want to make a metastatic cancer model,
there are easier and harder ways to do it.
This is one of the harder ways.
But you probably want to talk to a biologist
if you're a nanoparticle person and say,
what's a good metastatic model that we can make?
And the nice thing is the biologist will do this for you
and you can get that mouse that has metastatic cancer
and then start using that.
But it's just the next step.
And some people have gotten there, but really not enough
because I wasn't able to cite many of them
when I started doing this huge search for this kind of thing.
So they're out there, but you really got to talk to biologists.
You're lucky if you have someone that's making mouse models
for cancer really doing this.
But there are a lot of biologists doing this
and not so many engineers taking advantage yet.
And so that's kind of the main point.
Quickly, the stages of metastasis, a little introduction.
There's a billion pictures like this.
I just took the one that we published in the review that I was on.
But they all start, you get a primary tumor,
and then you have those primary tumor cells dissociate.
And they're basically signals and also a bunch of proteases
that start becoming active, becoming made.
And you end up getting primary tumor cells
that kind of break through the connective tissue.
And then you get intravasization,
which means getting into the blood vessel.
And once they've gotten through the blood vessel wall,
these tumor cells now are in the circulation.
And they're going through the vasculature,
and they're going to stop somewhere.
And it might be a site that the tumor can't live at,
in which case there won't be a metastatic lesion formed,
or it'll be somewhere that it can,
and it'll start to grow a distant metastasis.
And I don't want to talk too much about platelets,
but there's various things that happen in this circulation.
And sometimes platelets bind to tumor cells
and basically shield them from the immune system
so it doesn't see them and is able to metastasize.
And then they get out of the blood vessel wall,
it's called extravasation,
and then they're able to proliferate at a secondary site.
So this is the story, and it's basically a lot of,
it's a few steps, and all of them have potential
for therapeutic or diagnostic interventions.
There's a lot of signaling that's going on
and a lot of stuff that's made,
a lot of proteins that are made by the tumor
that are not endogenous to that tissue,
or at least not at a very high level normally.
And so there are MMPs and metalloproteinases,
proteinases that are being made
that are allowing it to break through the spermal layers.
And so there's a lot to detect,
including metabolites, proteins,
and even, as someone mentioned,
the big talk at ACR, there's also DNA.
And so there's a lot to detect that's even in the blood,
and maybe we can even think about detecting stuff
in other places.
And then I'll let you think about different ways
to go at these different stages
with a therapeutic mechanism.
Certainly if we can,
but what I'm going to talk a little bit about
is at these sites, after it's already gotten,
after the cancer's already metastasized, what do we do?
One thing to look at is where these sites are.
Where are the metastases occurring?
And so we looked at all these different cancers,
and the primary tumor is marked in blue here.
This is breast cancer, or one type of breast cancer,
and looked at where those metastases are happening.
And in this case of breast cancer,
you've got actually a lot of stuff going to lymph nodes.
And over 40% of breast cancer is at least metastasized
to these two lymph nodes.
You get metastasis to the lungs,
you get metastasis to the liver, and metastasis to bone.
Those are the major sites for breast cancer.
But we looked at a lot of other cancers, too,
and they're different.
The differences are caused by various things.
One is the fact that if you have a primary tumor here
and where the blood circulation is going after that
can dictate a lot.
About 66% of tumors of metastatic sites
can be predicted from this blood flow.
But there's also a lot of signaling molecules
and microenvironments that are playing into this as well.
And so the other 33% of tumors can't be described
by where the blood is going.
So if you want to look at some interesting places
to target your nanoparticles, well, here they are,
for metastasis and a bunch of other cancers, too.
But there's a lot of recurring organs here,
mainly the lungs, the liver, and the lymph nodes
are three major sites of metastasis
of many types of tumors.
And we already know how to get particles
into these pretty well.
Now, once they get there, you have to think about
what type of cells you're dealing with.
And so you do have to.
And so there's other considerations.
But just to get things in the lungs,
if you put positive charges on your particles,
and I'm talking about intravenous injection,
you can get about over 200 nanometers sizes.
You can get into the lungs.
The liver, between 100 and 200 nanometer particles
usually end up getting to the liver.
And lymph nodes, if you get a small particle,
maybe in the 50 nanometer range,
you put a sugar on that or polysaccharide,
you'll see a lot of localization.
So we can get things to these sites pretty readily.
We know how.
It's up to us to figure out ways of using this information
to make something that's efficacious.
And then once you're at that location,
or actually even playing into that,
you can also think about other types of targeting
that get you into certain cell types,
that bind you to certain things.
But the problem is if your particle is made
to go to the liver because it's the right size
and it's going to get in the liver,
then if you're putting an antibody on that,
some of those particles might get,
if you want the antibody to bind to something in the pancreas,
some of them might get there, but a lot of them aren't
because your original particle is destined to go to the liver.
And so you have to think about these big design considerations
and then you have to think about how you're going to target.
And so now I want to switch gears.
So that's kind of what I talked about in this review.
But I do want to have a little bit of time
to talk about what I've been doing.
One thing is, and this is really from my PhD work
and I'm transferring over to Memorial,
and it's actually why I was hired there.
And I was very floored, as maybe some of you will be.
But I was doing work on near-infrared fluorescent carbon nanotubes.
And basically a carbon nanotube is a hollow tube
that is one nanometer in diameter, more or less,
and if it's a single-walled carbon nanotube,
and it's one of about a third of the ones that are made
when they're synthesized, they'll be fluorescent.
And the range of fluorescence is around 850 to 1400 nanometers.
And you can make movies of these things floating around,
this was by people at Rice University,
and you can just watch them all day.
And they're actually stably fluorescent nanomaterials
that some people I've done some drug delivery with.
I'm not going to do any drug delivery with them
because they're really, well, they can be pretty long,
but they're not degradable, they don't fall apart.
So I've been using these for sensing
because they're reporters, they are fluorescent on their own,
this fluorescence is intrinsic, I'm not putting any tag on them.
And it's due to basically, in their density of states diagram,
there's these bands that result in absorbance and fluorescence.
And actually, if these particles are big, are not nanosized,
they're not going to give off this light.
Only at the one, basically bringing this down
to the one-dimensional scale will nanotubes give off any light like this.
And so I make a bunch of, and so at the band edge,
which is the lowest energy transition,
you can get fluorescence out of these nanoparticles.
And you can see them if you suspend them in water,
but not if you make just a solid chunk of them.
Or if they're kind of not, if they're all bound,
stuck to each other, you won't see anything.
And so you can see individual very narrow peaks of their fluorescence
throughout the near-infrared from here 900 to 1400 nanometers.
And each one of these peaks, and even the little shoulders,
are different nanotubes with slightly different diameters
and slightly different chiral structures or graphitic structures.
And it turns out that we can make a whole big map of these
where if we excite throughout the visible
and take emission throughout the near-infrared,
we can excite many of these.
More than this, if you take different types of samples,
you can get maybe 30 different nanotubes
that with each one of these maxima is a different nanotube species.
And they all have names based on, if you look at a graphitic lattice,
it's basically it coordinates on a graphitic lattice.
And so the ones with bigger numbers are bigger diameter nanotubes.
And so we have lots of different either optical probes
or sensors to play with here.
And so I've been using these mainly because they don't photobleach.
You can just excite these all day, even a single nanotube,
in a microscope with a laser, and you don't see any bleaching.
And you do with organic dyes like endocyanin green and even quantum dots.
So they're really stably fluorescent.
And they fall within the tissue transparent window,
the area where light can go through tissue,
where blood and tissue stop absorbing light around 700 nanometers.
Water absorbs light around 1,400 nanometers.
But in between, we get this window.
And we can even put them inside of a mouse and look at them.
So we can make in vivo sensors if we want or in vivo tags.
But we can certainly watch them all day if we put them inside of cells.
And their intensity won't degrade at all.
And we can have that cell live for as long as you want,
depending how we wrap that nanotube.
I'm not taking blank nanotubes that have nothing on them.
I'm actually wrapping them in polymers, proteins, DNA.
And that makes them very compatible with biological media
because you're basically candy-coating it with something
that's already used in biology or biocompatible.
So we can watch this stuff all the time or as long as we want.
And we can then see even changes in the emission,
depending on how we functionalize these.
And so here I put one nanotube on a surface and just watched it with,
oh, there it goes, and just watching the intensity.
And then I added some hydrogen peroxide, and this is wrapped in it
with a certain type of polymer to allow it to be sensitive
to the hydrogen peroxide.
And we can watch the intensity of the nanotube quench,
in fact, with these single steps,
which if you're a single-molecule biophysicist,
you know that this is actually due to single-molecule binding events.
And it's actually reversible.
The hydrogen peroxide can sit on the nanotube and quench the nanotube
and then come off and come back on.
And so we can actually watch this down to the single-molecule level,
at least in the stochastic method.
I'm not saying that I'm going to have a whole sample with one molecule
and then watch, wait for that molecule to hit the nanotube.
But we can see single-molecule binding events.
And so what I did at the very end of my PhD was I made,
I started wrapping nanotubes in things or binding nanotubes
to something that would have a binding site for a small molecule.
And I tried lots of small molecules, did a lot of screening,
and found that the best things that I found,
at least when I wrapped nanotubes with this peptide called bombolitin,
which is a B-venom peptide, is that it would bind explosives.
And so that's not exactly what I was going for.
I did not actually set out to make an explosive sensor.
But we had some explosives lying around the lab.
And it turns out that if you put a certain type of this bombolitin peptide
on the nanotube, it has a binding pocket that will bind to RDX.
And this binding event will occur.
And due to the fact that the nanotube's electrons are all on its surface,
because it's a hollow tube, you can get sensing events.
Basically, if anything perturbs the surface of the nanotube,
you can see a change in that emission.
And so I was able to make a, not that way.
So I was able to take a bunch of different nanotubes
with these different emissions and look at their intensities
and their wavelength changes.
And then I was able to take this one peptide-wrapped nanotube
and added a lot of different analytes.
Most analytes didn't cause a change,
but a few caused a change that actually were differentiable
due to the fact that the intensity and wavelength of these nanotubes can change
when you have this binding event.
We were able to see that we can not only detect RDX and picric acid
and actually a few pesticides, but we can even differentiate their signals.
So we were able to do multiplex detection with this one nanotube complex
and actually detect multiple analytes that gave us different signals.
So this is one way to make a nanosensor that maybe detects small molecules.
Hopefully, if I can make some that will detect cancer-related small molecules,
that might be cooler for me than explosives,
considering that I'm in a cancer center.
But this is kind of one direction to go.
And so one other set of results that I just wanted to show you,
the stuff that I've been doing in my postdoctoral work,
I've been making some nanoparticles.
These are actually nanogels.
And they're around in the 60s and 70s nanometer range.
And I've been using these for targeted delivery.
And when we throw these nanogels that are not targeted into mice,
we get this big blotch here.
Does anybody know what this location is in a mouse?
You're allowed to scream out.
Not the kidney. Kidneys are lower.
Liver. Very good.
That's nanogels that got into the liver.
We didn't put anything on them that made them go there.
It's just that they're the right size.
They're actually a little bit bigger than 70 nanometers.
They're still getting closer to 100 sometimes.
They're not 100% monodisperse.
And they're getting into the liver.
And when we put a target on them, a target molecule,
we found that we can get them to stop going to the liver,
at least to some extent.
But look where they're also going, though not to a huge amount.
We also see these spots on the left side right here,
left and right side here,
the armpits.
Does anybody know what those are?
Lymph nodes.
So we're able to basically take this non-targeting nanogel
and see it go both into the liver and the lymph nodes.
And when we put a small molecule targeting ligand onto it,
they went to the liver less.
The lymph node is still about the same amount.
But what they did start going to, to some extent, was bone.
And so we are able to get the liver to go down to some extent
Femur, we actually didn't see much difference.
But in the spine, we saw an increase
when we put this targeting ligand,
which is an alendronate, a bisphosphonate,
basically a small molecule osteoporosis drug.
And we wondered why are they not binding to femur anymore,
but they're binding to spine.
And so we did a little bit more studying.
We found that we have, this is marrow here.
This is a slice through the femur.
And this is marrow.
And the red is a nanoparticle.
And the blue is basically kind of autofluorescence of the marrow.
And then in this area is bone.
And when we have a non-targeted particle,
especially in the femur, which has a lot of marrow
and not so much surface area where the bone is,
we see all the stuff in the marrow.
And then also, if you look in the spine,
we see everything in the marrow here as well
and not in the bone, which is here.
And so that makes sense.
These got taken up probably by macrophages.
And some of them, it turns out, didn't.
But if we put this targeting ligand on,
we were able to see that a lot of particles line the bone
in that marrow cavity.
And so we had this lining basically binding to the bone,
to the surface of the bone.
And we saw the same thing in the spine.
And so the reason we think actually that these looked
like they bound more to the spine
instead of the femur when we targeted them
was actually the fact that there's a lot more surface area
here where you have marrow and bone next to each other.
And you basically just have this big marrow cavity
in the femur.
And so that's what I've been doing in terms
of the therapeutic side.
I haven't actually put any drugs inside of this.
I just wanted to see how well I can target
and whether I can figure out the mechanism of why.
And it looks like we're actually getting pretty good binding.
And so on that note, I just have a couple of statements.
One is if you are a biologist, find these guys,
or these guys, engineers.
And if you're an engineer, find some biologists to talk to.
And if you are nearby, maybe even some clinicians
because this is a good trio.
And I think someone up here, maybe a patient advocate.
Those are actually really good people to talk to as well.
And just get talking.
And so to my alma mater, I have some suggestions
from a top-down approach.
I suggest you be able to advertise all these biology,
chemistry, physics, engineering, medicine, et cetera,
seminars a little bit more freely.
Maybe make it very easy to get on the seminar list,
the email list, the list serve, the junk mail serve.
Because in fact, you might find something that goes by
that mailbox that captures your interest
and makes you go to that seminar.
And that's really important, just getting out there.
And then keep having things like this.
Good job, people.
And from the bottom-up point of view,
go ahead and start attending those seminars
outside of your field.
If you're an engineer, get to that biology seminar
even if you don't know what's going on.
And I certainly didn't know what was going on
and still don't know what's going on
and maybe 80% of the time.
But I'll skip down to this here.
Use your smartphone at seminars to Google or Wikipedia
things that you don't understand.
That saves you.
Sometimes you're able to learn enough in that Wikipedia page
to then stump the speaker.
I didn't do that on purpose, but it did happen.
And also, don't be shy about telling others
about your research.
Sometimes you meet someone and you just never get there.
And I had a friend that we met.
We were both night owls.
We'd see each other day in and day out.
And then it only happened like a year later
when we really talked about our research
and realized, wow, we have this awesome reason to collaborate
or awesome thing to collaborate on.
And we could have started this six months ago
if we just had opened our mouths
when we were going out to coffee.
So just don't be shy.
And don't just talk about the basketball team.
Talk about some other things.
Sometimes just opening your mouth is the way to do it.
And then also, when you go to these seminars
and ask them naive questions
and get people, even if you maybe could embarrass yourself,
I highly recommend it.
So with that, I'd like to thank some people.
Backed in my PhD, the Strano Research Group
and a lot of people there.
And then currently in the Langer Laboratory,
there's quite a lot of people to thank,
including Dan Anderson with my work
and a lot of collaborators, some of whom are here,
and my funding from the Damon Runyon Cancer Research Foundation
and my upcoming lab,
where we're going to do interesting nanotherapy
and imaging and sensing work
with these people who are going to come out with me
starting in June to Memorial Sloan Kettering.
And I'll leave this up and take any questions.
That's an excellent question.
So in that case, we didn't purify anything.
The nice thing was that if you saw that spectrum,
you can pretty much differentiate these peaks,
the fluorescent peaks,
just taking one spectrum with a 785 nanometer laser,
and we can see maybe 8 to 10 different nanotube peaks.
And because the full or half max of these peaks is very narrow,
we can see all of them.
We don't really have to do any real deconvolution.
We just stick them to Gaussians,
and we look at their intensity and their wavelength.
But your other part of that question was,
can you purify these?
And the answer is, it's getting better, but it's not easy.
But yes, soon you'll be able to buy your own vial of 6-5 or 7-5,
these individual species of carbon nanotubes.
And the really interesting thing is they won't be black anymore.
They'll be different colors
because they have one narrow absorption peak in the visible.
So one day you'll be able to buy blue carbon nanotubes,
red carbon nanotubes.
The only difference is that they're made of exactly the same thing,
but they have slightly different gravitic structure.
So I haven't injected carbon nanotubes more than maybe once into animals,
and they weren't passivated nearly the right way,
and they aggregated, and that was really bad.
But that wouldn't prevent me from trying again.
I would just coat them with something completely different.
So if one can coat nanotubes with something that will passivate them,
just like nanoparticles,
and prevent them from being taken up by something,
they'll have a completely different response than nanotubes
that are not wrapped in anything and aggregate.
So in my case, I just put them in cells.
They didn't show any cytotoxicity.
In animals, you can basically,
the nice thing about nanomaterials is that depending on what you do with their surface,
it will change the properties completely as to what happens in animals.
I have a question.
My favorite kind.
So my question is, what is the opportunity for nanomanagement?
As you mentioned, so we've got to have more nutrients than pesticides,
and by the structure of the cell,
what is the functionality of nanostructures in your system?
So how do you use nanomaterials?
How do you efficiently treat the pesticides?
Well, I actually disagree.
I think the best reason to use nanomaterials is that you can put anything you want on top of them,
and so you can put a red blood cell on them,
or basically the membrane of a red blood cell on them,
or you can put a sugar on them,
or you can put something else, an antibody on them,
and you can put something that will get them to put a targeting ligand on them,
and I think the targeted delivery in terms of getting them to the right type of tissue is going to work.
You just have to, but it's not as simple as just saying,
okay, I put a targeting ligand for the pancreas,
and it goes to the pancreas,
because you have to also deal with the fact that these want to go to certain locations,
which are often metastatic sites,
but you have to deal with the bulk, the charge, the size,
and then you have to also deal with the surface properties.
So as long as you get all those ducks in a row, as you would say,
I think you can do some really good metastasis targeting work.
Sure.
Well, in terms of the fluorescence,
a lot of people have done electronic sensors.
In terms of detecting other things,
I guess that was just my last work in my PhD,
so I wanted to highlight it because it was a way to basically detect something that didn't have a special property,
like we were able to detect radicals, free radicals, ROS, singlet oxygen, hydroxide,
and those things that have special properties, like they're very redox active, for instance,
and so we're able to do a lot of interesting work where we're looking at free radicals, for instance,
but I wanted to go towards detecting something that didn't have a special property like that,
that just was any random small molecule, like an explosive,
and so in that case, you can basically, what that peptide was, was a binding site for an explosive,
but if you make another molecule, then you have a binding site on the nanotube,
and you can theoretically detect that, and we have done a little bit of protein sensing.
It hasn't been super great yet, but we can put an antibody on nanotube
and then detect an antigen.
We actually did that with troponin, a heart attack biomarker,
and that publication should probably come out in the next few months.
You can put lots of antibodies on that carbon nanotube and then detect,
and then you have a lot of binding sites for your antigens.
That's a similar question.
If the RDX was present in water or a mixture,
you are able to detect it.
Right. We weren't really going for explosives in terms of a real,
we weren't engineering these things for a form factor for explosives.
You would want, you know, air, you know, detection in air.
In this case, they were peptide rat nanotubes in water.
We added RDX to water.
It's not very soluble, but it gets in a little bit, and we were able to detect that.
If you want to go to real detection of explosives,
we never even tried putting these in air and having explosives bind to them.
You probably would want to do maybe a pre-concentration step or something.
It is possible to think about this being actually applied for explosives,
but we're just not there yet.
Right.
Right, exactly.
So this was specific for basically nitroaromatics.
We were able to detect a lot of different nitroaromatic molecules,
like a couple pesticides and a couple explosives,
but we really were able to see,
the nice thing was we were able to see a very different response to those things
than anything else that might be a contaminant.
There are some other contaminants that we can detect.
In fact, we were able to detect neurotransmitters,
which usually aren't going to be mixed with explosives,
but if they were, we'd see a very different response.
One more.
Thank you for a really interesting talk.
I can understand about 65%, so I thought that was really good.
I was wondering if you could take a little leap of the time machine with me for a moment
and just tell us what you think.
How is this going to apply to a patient?
What is your hope that in the end result,
if you have a metastatic patient showing up at a clinic,
what will this mean for them?
I mean, so on the therapy side,
it's basically an extrapolation from any other drugs,
except these drugs will be able to target these metastatic sites
so that someone that does unfortunately present with stage 4 metastatic cancer
has more hope,
but I think that's the dream of anyone making any sort of therapies,
is can someone come in that happens to have presented with stage 4 cancer
and now they have hope because they have targeted therapies
that will go to all these metastatic sites and actually do something there.
So that's certainly kind of the easy extrapolation.
The other thing is can we actually make something
that will interface with patients to detect cancer
way before it gets to stage 4 metastatic,
where either someone needs to go into the doctor only once a year
and you just do a quick scan,
or one of the thoughts was that if someone has a primary tumor
and you want to figure out if it switches to metastatic,
can you even implant something that detects the blood all the time
and then when a metastatic marker starts coming out,
it says, oh, your cancer has now become metastatic.
And so there's multiple different ways to go
from kind of just extrapolating what's happened
to maybe having something implantable and doing something really exotic.
Okay, let's thank our speaker one more time.